|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006104,
umls-concept:C0010132,
umls-concept:C0022661,
umls-concept:C0024554,
umls-concept:C0205147,
umls-concept:C0231491,
umls-concept:C0441655,
umls-concept:C0597357,
umls-concept:C0681850,
umls-concept:C1280500,
umls-concept:C1512045,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-21
|
|
pubmed:abstractText |
Corticotropin-releasing factor receptor type 1 (CRF(1)) antagonists have been proposed as therapeutic agents in the treatment of mood and anxiety disorders although clinical evidence supporting their development and understanding of a dose-response relationship has been lacking.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1432-2072
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
208
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
109-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19911168-Adult,
pubmed-meshheading:19911168-Brain,
pubmed-meshheading:19911168-Cross-Over Studies,
pubmed-meshheading:19911168-Dose-Response Relationship, Radiation,
pubmed-meshheading:19911168-Double-Blind Method,
pubmed-meshheading:19911168-Fluorodeoxyglucose F18,
pubmed-meshheading:19911168-Glucose,
pubmed-meshheading:19911168-Humans,
pubmed-meshheading:19911168-Male,
pubmed-meshheading:19911168-Positron-Emission Tomography,
pubmed-meshheading:19911168-Receptors, Corticotropin-Releasing Hormone,
pubmed-meshheading:19911168-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects.
|
|
pubmed:affiliation |
Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium. mschmid4@its.jnj.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
